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Purpose: This cost analysis aimed to quantify the cost of IGRT in relation to IGRT frequency and modality
with Cone Beam Computed Tomography (CBCT) or orthogonal electronic portal imaging with ﬁducial
markers (EPI-FM).
Material and methods: Patients undergoing IGRT for localized prostate cancer were randomized into two
prostate control frequencies (daily or weekly). Costs were calculated based on the micro-costing results
according to hospitals’ perspectives (in Euros, 2009) and the time horizon was radiation therapy.
Results: A total of 208 patients were enrolled in seven French cancer centers. A total of 6865 fractions
were individually analyzed. The mean total treatment fraction duration was 21.0 min for daily CBCT
and 18.3 min for daily EPI-FM. Increasing the control frequency from weekly to daily increased the mean
treatment fraction duration by 7.3 min (+53%) for CBCT and 1.7 min (+10%) for EPI-FM (p 6 0.01). The
mean additional cost per patient of daily controls compared with weekly controls was €679 and €187
for CBCT and EPI-FM, respectively (p < 0.0001).
Conclusions: The incremental costs due to different prostate IGRT strategies are relatively moderate, sug-
gesting that daily IGRT combined with intensity-modulated RT (IMRT) could be administered in cases of
high-dose radiation delivery to the prostate.
 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 106 (2013) 50–58Accurate prostate localization is critical in prostate cancer
radiotherapy, particularly for highly conformal techniques such
as intensity-modulated radiotherapy (IMRT), which deliver high
doses of radiation to the prostate. Intra-pelvic prostate motion
can reach up to 2 cm along the anteroposterior axes, mainly due
to rectal volume variations, while planning target volume (PTV)
margins are commonly less or equal to 1 cm. Rectal distension on
planning computed tomography (CT) has consequently been
shown to increase the risk of recurrence [1,2].
In the ‘‘standard historical’’ setting, electronic portal imaging
(EPI) without ﬁducial markers only corrects for patient position.
Image-guided radiotherapy (IGRT) has therefore been gradually
developed in order to correct for prostate localization. The two
main prostate IGRT modalities currently used are orthogonaladiotherapy, Eugène Marquis
ue, CS 44229, 35042 Rennes
r (R. de Crevoisier).
er CC BY-NC-ND license.imaging (EPI or kilovoltage) combined with intra-prostatic ﬁducial
markers and cone beam CT (CBCT). Cost studies, although limited
in number, suggest that IGRT is particularly costly, mainly because
of the increase in treatment fraction duration, although this is
dependent on IGRT modality [3,4]. In addition, the optimal posi-
tioning control frequency has not yet been clearly established,
which also potentially affects the cost of IGRT [3]. Daily controls
correct for both systematic and random prostate displacements.
Day 1, 2, 3, and weekly controls (which deﬁne the average prostate
position during treatment) only correct for systematic prostate dis-
placements. The dosimetrical consequences of systematic and ran-
dom geometrical uncertainties differ, with the deteriorating effects
of random variations being much smaller than those caused by sys-
tematic deviation [5,6].
Therefore, we designed a randomized study that aimed to com-
pare daily controls with weekly controls in prostate cancer IGRT, in
terms of both clinical outcome and cost. This paper presents the
cost analysis of the two IGRT frequency strategies, in relation to
IGRT modality (CBCT or ﬁducials) in several French cancer centers.
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Study population
The inclusion criteria were patients with localized prostate ade-
nocarcinoma, N0 or N, without metastasis assessed by abdomi-
nopelvic CT and bone scan. Patients had to undergo 3D
conformal radiotherapy, with or without IMRT, and with or with-
out androgen deprivation, depending on risk group. The total dose
could range from 70 Gy to 80 Gy in the prostate and could reach
46 Gy in the seminal vesicles. The dose per fraction was 2 Gy. Tar-
get delineation and dose distribution had to respect the French
Study Group on Urogenital Tumors guidelines [7]. The PTV margins
were deﬁned as 1 cm all around the prostate and the seminal ves-
icles except in the posterior direction where the margin was only
5 mm. All patients provided informed consent. Exclusion criteria
were patients with hip prostheses, pacemakers and target volume
including the pelvic lymph nodes.Study design and IGRT procedure
The cost analysis was performed prospectively in a multicenter
randomized phase III trial within the framework of the French Na-
tional Cancer Institute (INCa). Patients were randomized into two
prostate IGRT control frequency groups: daily control or weekly
control (day 1, day 2, day 3, then weekly, with average prostate
positioning on the days when prostate position was not con-
trolled). IGRT modalities consisted of CBCT or ﬁducials visualized
using orthogonal EPI, depending on center practice. A radiation
oncologist was required to approve patient position for CBCT but
not for EPI with ﬁducials. Patients with protocol deviations were
excluded from the study. Deviations were deﬁned as more than
three fractions without prostate positioning control in the daily
setting arm, and more than ﬁve supplementary fractions with
prostate positioning control in the weekly setting arm.Cost assessment
Economic analysis was performed from the perspective of each
hospital during the trial. Data on consumption of resources were
prospectively collected from the beginning of the ﬁrst irradiation
fraction, until the end of the last fraction. Calculations were strictly
based on a micro-costing approach [8]. Only resources that entered
the hospital production process and which were likely to vary be-
tween the strategies being compared were considered. Case report
forms were used to collect resource utilization data for all irradia-
tion fractions, and when appropriate, for the implementation of
ﬁducial markers. Unit prices and costs were provided by the
accounting departments of the centers participating in the study.
All costs were expressed in €, and all taxes included. The time re-
quired from staff and the duration of irradiation and operating
room occupation (for ﬁducials) were assessed for each patient by
direct measurement using chronometers. The mean yearly wage
costs were calculated based on what a staff member would earn
after 10 years of professional experience. The linear lifetime period
for the linear accelerator was 12 years. As the future number and
types of upgrades they will receive remain uncertain, an estima-
tion of stationary conditions over a period of 12 years was made.
The annual operating time of the linear accelerator was estimated
(from questionnaires) to amount to 2600 h, corresponding to
52 weeks per year, 5 days per week, and 10 h per day (ranging from
7.5 h to 12.5 h). The time per year required for internal mainte-
nance and quality control of the accelerator by the physicist was
estimated to amount to 392 h with CBCT and 357 h without CBCT.
Time per year for the medical technician was 64 h with CBCT and
zero without CBCT. The linear lifetime period of the software wasﬁve years. The unit costs of the operating room, including consum-
ables and clinical infrastructure (equipment), were obtained from
the accounting departments of the participating centers. All formu-
lae are shown in Table 1.
It must be noted that the aim of the present study was not to
estimate the overall cost of radiotherapy. Thus, only factors that
potentially affected IGRT cost were selected. Incremental costs
were ﬁnally calculated between daily and weekly positioning fre-
quency for IGRT, with CBCT or ﬁducial markers.Statistical analysis
The number of patients intended to be included in the cost anal-
ysis was 200. Based on unpublished pilot work, 50 patients per arm
were considered sufﬁcient to ensure a signiﬁcant difference be-
tween costswith a statistical power of 80%. Patient anddisease char-
acteristics, along with resource consumption and costs, were
summarized using descriptive statistics. Univariate differences be-
tween the study armswere determined using Pearson’s chi-squared
or Fisher’s exact test for categorical variables, and the Wilcoxon–
Mann–Whitney test for continuousvariables.Multiple linear regres-
sions were performed to model the relationship between the total
cost and potentially explanatory variables (IGRT frequency and
modality, use of IMRT, age, WHO performance, Gleason score, pros-
tate-speciﬁc antigen (PSA), TNM stage, D’Amico risk classiﬁcation,
androgen deprivation, total radiation dose, and hospital status).
The mean cost sensitivities of the different IGRT strategies (CBCT
orﬁducialmarkers,withdaily orweekly imaging) to variations in re-
sources consumption and unit cost parameters were assessed inde-
pendently. Variations of ±10% in the value of each parameter were
retained and illustrated graphically within Tornado diagrams [9].
Uncertainties regarding costs were also assessed by probabilistic
analysis using non-parametric bootstrap methods: 1000 simulated
bootstrap samples were generated by independent draws for CBCT
orﬁducialmarkers,withdaily orweekly imaging. All 95%conﬁdence
intervals were computed. All analyses were performed using SAS
v.9.1 (SAS Institute, Cary, NC), STATA v.11.0 and Treeplan SensIt.Results
Patients and treatment characteristics
Between January 2007 and May 2012, 420 patients were in-
cluded in this randomized trial comparing the two IGRT control
frequencies with clinical outcome evaluation as the main endpoint.
The ﬁrst 208 patients were enrolled for the cost-analysis from
January 2007 to May 2011 in ﬁve French cancer centers located
within academic institutions (Léon Bérard (Lyon), René Gauducheau
(Nantes), Jean Godinot (Reims), Eugène Marquis (Rennes), Henri
Mondor (Créteil)) and two private radiation centers (Sainte
Catherine (Avignon) and Pont de Chaume (Montauban)). Twenty-ﬁve
patients were excluded from analysis due to protocol deviation
as previously described. Among the 183 analyzed patients, 93
patients had daily control and 90 patients had weekly control.
CBCT was used for 128 patients and ﬁducial markers for 55
patients. A total of 6865 fractions were individually analyzed
(4772 fractions with CBCT and 2093 with ﬁducial markers).
Patient, tumor and treatment arm data are presented in Table 2.
These characteristics were not statistically different between the
two randomized arms, except for the total number of fractions
and the radiotherapy technique in the case of CBCT.Resource consumption
Table 3 illustrates the time spent by staff and treatment room
occupation duration per irradiation fraction according to IGRT
Table 1
Description of IGRT cost assessment.
Cost of IGRT for the
patient ia,b
Formulas
Cost of staff:
(dosimetrist, medical
physicist, medical
technician, radiation
oncologist)c
¼
X4
personnel¼1
mean yearly wage costð€Þ
mean annual working timeðhoursÞ
 
 time required for IGRT of patient i ðhoursÞ
 
Cost of linear acceleratorc
¼
catalog priceð€Þ
linear lifetime periodðyearsÞ
annual operating time of linear acceleratorðhoursÞ
 !
 duration of irradiation room occupation for IGRT of patient i ðhoursÞ
" #
Cost of external
(subcontracting)
maintenance and
quality control
(EMQC)c
¼ annual mean cost of EMQCð€Þ
annual operating time of linear acceleratorðhoursÞ
 
 duration of irradiation room occupation for IGRT of patient i ðhoursÞ
 
Cost of internal
maintenance and
quality control
(IMQC)c by medical
physicist and medical
technician
¼
X2
p¼1
mean yearly wage costð€Þ
mean annual working timeðhoursÞ
 
 time required for IMQCðhoursÞ
 
þ Cost of software
mean purchase priceð€Þ
linear lifetime periodðyearsÞ
annual operating time of linear acceleratorðhoursÞ
 !
 duration of irradiation room occupation for IGRT of patient i ðhoursÞ
" #
Cost of implementation
of ﬁducial markersc by
urologist and
registred nurse ¼
X2
p¼1
mean yearly wage costð€Þ
mean annual working timeðhoursÞ
 
 time required for implementation of fiducial marker of patient i ðhoursÞ
 
þ Costs of operating room : ðmean unit cost of operating roomðhoursÞ
 duration of operating room occupation for implementation of fiducial markers of patient i ðhoursÞÞ
þ Costs of fiducial markers : ðmean unit price of fiducial markerð€Þ  quantity of markers for patient i ðhoursÞÞ
a Cost of IGRT with CBCT for the patient i corresponds to the sum of the cost of staff (dosimetrist, medical physicist, medical technician, and radiation oncologist), the cost of linear accelerator with CBCT, the cost of external
maintenance and quality control (EMQC), and the cost of internal maintenance and quality control (IMQC), including the cost of software (Artiscan).
b Cost of IGRT with ﬁducial markers for the patient i corresponds to the sum of the cost of staff (dosimetrist, medical physicist, medical technician, and radiation oncologist), the cost of linear accelerator without CBCT, the cost of
external maintenance and quality control (EMQC), the cost of internal maintenance and quality control (IMQC), excluding the cost of software (Artiscan), and the cost of implementation of ﬁducial markers.
c Times were assessed by direct measurement using chronometers.
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Table 2
Patients and treatment according to IGRT modality and control frequency.
Characteristics CBCT EPIf with ﬁducial markers
Imaging frequency Imaging frequency
Daily (n = 67) Weekly (n = 61) p-Valuee Daily (n = 26) Weekly (n=29) p-Valuee
Age (mean, range)a 71 (56–83) 72 (54–85) 0.45 68 (54–76) 70 (52–78) 0.42
WHO performanceb
0 64 (96%) 55 (92%) 0.10 25 (96%) 29 (100%) 0.47
1 1 (1%) 5 (8%) 1 (4%) 0 (0%)
Gleason score
66 17 (25%) 13 (21%) 0.71 5 (19%) 3 (10%) 0.26
7 38 (57%) 37 (61%) 20 (77%) 21 (72%)
P8 12 (18%) 11 (18%) 1 (4%) 5 (17%)
PSA in ng/mL (mean (SD)c 12.3 (12.6) 9.8 (6.6) 0.66 13.1 (11.7) 11.1 (10.9) 0.16
TNM stage
T1 22 (33%) 16 (26%) 0.61 6 (23%) 6 (21%) 0.94
T2 30 (45%) 28 (46%) 13 (50%) 14 (48%)
T3 14 (21%) 17 (28%) 7 (27%) 9 (31%)
T4 1 (1%) 0 (0%) 0 (0%) 0 (0%)
D’Amico risk classiﬁcation [21]
Low risk 12 (18%) 10 (16%) 0.36 2 (8%) 2 (7%) 0.83
Intermediate risk 30 (45%) 21 (35%) 10 (38%) 14 (48%)
High risk 25 (37%) 30 (49%) 38 (54%) 13 (45%)
Androgen deprivation
66 months 36 (54%) 32 (56%) 0.99 13 (50%) 17 (58%) 0.79
>6 months 13 (19%) 12 (18%) 1 (4%) 1 (4%)
No androgen deprivation 18 (27%) 17 (28%) 12 (46%) 11 (38%)
Total radiation dose, median (range) 74 (70–80) 74 (70–80) 0.25 80 (74–80) 80 (76–80) 0.59
Radiation duration (days), median (range) 56 (50–106) 57 (50–72) 0.55 61 (55–71) 61 (25–72) 0.55
Number of radiotherapy fractions, mean (SD) 37 (1) 38 (1) 0.01 39 (1) 39 (1) 0.59
Radiation therapy technique
IMRTd (only) 29 (43%) 24 (39%) 0.01 25 (96%) 29 (100%) 0.47
3D conformational radiotherapy (only) 28 (42%) 36 (59%) 1 (4%) 0 (0%)
Combined 3D conformal radiotherapy (without IMRT)
and IMRT (boost in the prostate)
10 (15%) 1 (2%) 0 (0%) 0 (0%)
a In years at diagnosis.
b World Health Organization.
c Prostate speciﬁc antigen.
d Intensity-modulated radiation therapy (IMRT).
e Non-parametric tests (chi-square and Wilcoxon Mann–Whitney tests).
f Electronic portal imaging.
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pared with the weekly control, the daily control signiﬁcantly in-
creased radiation oncologist and radiotherapist intervention
duration and treatment room occupation duration for both IGRT
modalities. Regardless of the control frequency and IGRT modality,
treatment room occupation duration signiﬁcantly decreased during
the ﬁrst three fractions and comparedwith the rest of the treatment,
as shown in Fig. 3A (CBCT) andB (ﬁducialmarkers). For days 1, 2, and
3, and weekly CBCT, the mean fraction duration doubled between
the ﬁrst three days of treatment (24.5 min (SD: 6.1 min)) and subse-
quent treatment (day 4-end) (12.5 min (SD: 2.8 min)) (p < 0.01). In
the case of EPI with ﬁducial markers, the results were: 22.0 min
(SD: 3.3 min) and 15.5 min (SD: 1.3 min), respectively (p < 0.01).
The mean times for image acquisition were: 4.6 min (SD: 4.5 min)
for CBCT, and 3.6 min (SD: 1.6 min) for EPI with ﬁducial markers.Unit costs
Themean hourly staff costswere: €81 (ranging from €62 to €100)
for radiation oncologists and urologists, €56 (ranging from €49 to
€62) for physicists, €30 (ranging from €24 to €37) for dosimetrists,
€33 (ranging from €30 to €36) for registerednurses, and €27 (ranging
from €17 to €33) for radiotherapists. The catalog prices (for France)
were: €1,379,110 for the linear accelerator without CBCT and
€1,817,005 with CBCT. The mean yearly costs for external mainte-
nance and quality control contracts were: €108,416 (ranging from
€41,860 to €178,802) without CBCT and €120,974 (ranging from€41,860 to €191,360) with CBCT. The mean unit cost of dedicated
software for internal maintenance and quality control of linear
accelerators with CBCT was €16,236 (ranging from €7,050 to
€35,000). For ﬁducial marker implementation, the unit hourly cost
for the operating room was €228 (ranging from €219 to €238) and
the unit cost for markers €98 (ranging from €50 to €220).Mean costs according to IGRT modality and control frequency
Table 4 shows the mean costs per patient according to IGRT fre-
quency and modality (in €, 2009). Daily control was a more expen-
sive strategy than weekly control. The mean incremental cost for
CBCT reached €679 (SD: €69.6) with daily control compared with
weekly positioning (p < 0.0001). The incremental cost parameters
were represented by: staff (45% of the incremental cost), the linear
accelerator (28%), and maintenance and quality control (27%).
For ﬁducial markers, the mean incremental cost reached €187
(SD: €39.7) for daily positioning compared with weekly
(p < 0.0001). The incremental cost parameters were represented
by: staff (34%), maintenance and quality control (33%), the acceler-
ator (29%), and ﬁducial marker implementation (4%).
Multiple linear regression analysis showed that IGRT frequency
(t = 10.87; p < 0.0001) and the use of IMRT (t = 3.30; p = 0.0012)
were predicting factors of total cost (adjusted R2 = 0.4274). Patient
and tumor characteristics, androgen deprivation, total radiation
dose, and hospital status (private or public) were not signiﬁcantly
associated.
54 Cost of IGRTSensitivity analysis
Figs. 1 and 2 show the Tornado diagrams illustrating the impact
of ±10% variation in parameters were taken into account in the cal-
culation of costs for CBCT-based IGRT with daily or weekly controls
and ﬁducial-marker-based IGRT with daily or weekly controls,
respectively. The vertical lines, which represent the mean cost
when all parameters assume their base values, are at €2311 for
CBCT with daily imaging and €1632 for CBCT with weekly imaging,
and at €2065 for ﬁducial markers with daily imaging and €1878 for
ﬁducial markers with weekly imaging. Regardless of the IGRT fre-
quency or modality, the most sensitive parameter was the annual
operating time of the linear accelerator, followed by occupation of
the irradiation room. For CBCT with daily imaging, increasing the
annual operating time of the accelerator by 10% decreased the
mean cost from €2311 to €2217. Using non-parametric bootstrap
methods, 95% conﬁdence intervals for the mean IGRT costs were
[€2211–€2411] for daily CBCT scanning, [€1538–€1726] for weekly
CBCT scanning, [€2005–€2125] for daily ﬁducial markers, and
[€1829–€1927] for weekly ﬁducial markers (Fig. 4).Discussion
There have been great advances in radiotherapy over the last
three decades, with a succession of technical innovations including
the passage from 2D to 3D conformational techniques in the 1990s,
IMRT in the 2000s, and IGRT, stereotactic and respiratory-gated
radiotherapy and arc-IMRT more recently. Each of these increas-
ingly complex techniques has led to clinical beneﬁts, but with an
increase in cost. Indeed, a considerable increase in total radiother-
apy cost has been observed over the last decade, resulting from
higher capital investments and staff expenses [10].
The beneﬁts of using IGRT in combination with IMRT in prostate
cancer have been clearly demonstrated, and a recent survey on
IGRT in the U.S. has shown that the most common disease site
was the genitourinary system (91%) [11]. However, only a very lim-
ited number of studies show that IGRT is of clinical beneﬁt. In
2009, the preliminary clinical results from our randomized study
described a series of 107 patients who underwent IGRT (CBCT in
67%, ﬁducial markers in 28%, and ultrasounds in 5%), with a median
total dose of 76 Gy (70–80) [12]. Grade 2 and 3 acute rectal toxicity
rates were only 7% and 0%, respectively. More recently, a retrospec-
tive comparison by Zelefsky et al. showed that daily IGRT with
ﬁducial markers in combination with high-dose IMRT was associ-
ated with an improvement in biochemical tumor control, and moreTable 3
Required time from staff and room occupation duration per treatment fraction, according
CBCT
Imaging frequency
Daily (n = 67)
mean (SD)
Weekly (n =
mean (SD)
Time required from staff (minutes)
Radiation oncologist 3.2 (2.5) 1.1 (1.0)
Physicist 0.8 (1.5) 0.4 (0.7)
Radiotherapists (number of 2 to 3 per
fraction)
44.3 (7.5) 28.7 (5.8)
Duration of treatment room occupation (minutes)
Treatment room occupation 21.0 (3.9) 13.7 (3.2)
Treatment room occupation with imaging
control
21.2 (3.7) 20.9 (3.0)
Treatment room occupation without imaging
control
NA 11.2 (3.6)
NA (non applicable); SD (standard deviation).
a Non-parametric test (Wilcoxon Mann–Whitney tests).
b Electronic portal imaging.surprisingly, with a lower rate of late urinary toxicity [13]. The
optimal frequency and modality (CBCT or kV imaging EPI with
markers) of prostate image-guided repositioning are not clinically
well established, and nor is the impact of such factors on cost.
Therefore, the aim of the present randomized study was to quan-
tify the additional cost of daily prostate control compared with
weekly control, as well as different IGRT modalities.
The results of the duration estimations performed here are rel-
atively consistent with the limited data available in the literature.
Indeed, our mean time for CBCT acquisition was 4.6 min, which is
comparable with the results of Ploquin et al., who reported an
acquisition time of 4 min [3]. Mean total fraction duration using
a daily CBCT was 21 min in our study. Tuomikoski et al. reported
20–25 min duration for bladder IGRT with daily CBCT [14]. More-
over, Murthy et al. indicated that a tomotherapy-based IGRT frac-
tion required 21 min (also in bladder cancer radiotherapy) [15].
Here, the mean fraction duration estimated using daily EPI with
ﬁducial markers was 18 min. This result was higher than recent
ﬁndings by Gill et al. [16], who found a median time of 10 min.
Our higher estimation could be explained by the fact that we mea-
sured the entire treatment room occupation time (from the entry
of the patient to the treatment room until departure), while Gill
et al. restricted the time measurement to radiation delivery and
set-up time [16].
The present study shows that the duration of the treatment
fraction was almost doubled by the use of CBCT, compared with
treatment with no image guidance (from 12 min to 21 min). In
the Department of Radiotherapy at Dresden, the implementation
of IGRT increased the in-room time per fraction by an average of
32% for an orthogonal X-ray system and by 84% when an in-room
CT on rails was used, compared with conventional wall-lasers set-
up [17]. The speciﬁcity of the IGRT procedure (comprising image
acquisition and reconstruction, radiation oncologist validation
and couch repositioning) and modality at each center may have
had a signiﬁcant effect on duration. The treatment time has there-
fore been shown to be shorter in cases involving orthogonal kV
imaging and automated couch shift than in cases where EPI and
manual couch shift were used [4]. In our study, the radiation oncol-
ogists had to validate each prostate registration in real time when
using the CBCT. They were however not present in case of EPI with
ﬁducial markers based IGRT procedure. The ﬁducial markers regis-
tration was performed by the radiotherapists only, which was less
time consuming than the CBCT procedure.
Our results also indicate that the use of CBCT compared with
ﬁducial markers increased the treatment fraction duration by onlyto IGRT modality and control frequency.
EPIb with ﬁducial markers
Imaging frequency
61) p-Valuea Daily (n = 26)
mean (SD)
Weekly (n = 29)
mean (SD)
p-Valuea
0.06 0 0.1 (0.1) p < 0.01
0.12 0.1 (0.1) 0.1 (0.3) 0.99
0.01 33 (3) 30 (4) p < 0.01
0.01 18.3 (3.9) 16.6 (3.7) p < 0.01
0.08 18.2 (3.7) 18.8 (4.6) p < 0.01
NA NA 15.5 NA
Table 4
Mean costs per patient according to IGRT frequency or modality (in €, 2009).
Cost items CBCT EPIf ﬁducial markers
Imaging frequency Imaging frequency
Daily (n = 67)
mean (SD)
Weekly
(n = 61)
mean (SD)
D mean
costsa(SD)
p-Valueb Daily (n = 26)
mean (SD)
Weekly
(n = 29)
mean (SD)
D mean
costsa (SD)
p-Valueb
Staff Radiation
oncologist
159 (42.8) 64 (59.1) 95 (9.2) p < 0.0001 0 (0) 4 (7) 4 (7) 0.01
Physicist 14 (42.8) 10 (20.3) 4 (5.8) 0.63 3 (5) 4 (9) 1 (1.9) 0.81
Radiotherapist 706 (131.2) 500 (123.8) 206 (22.5) p < 0.0001 628 (69) 559 (65) 69 (18.1) p < 0.001
Total 879 (197.5) 574 (127.3) 305 (29.1) p < 0.0001 631 (71) 567 (70) 64 (19.0) p < 0.01
Linear accelerator 728 (133.9) 538 (131.5) 190 (23.5) p < 0.0001 539 (50) 485 (38) 54 (12.1) p < 0.01
Maintenance and
quality control
(QC)
Internal
maintenance and
QCc
113 (20.9) 84 (20,5) 29 (3.7) p < 0.0001 94 (9) 84 (7) 10 (2.2) p < 0.01
External
maintenance and
QCd
582 (107.0) 429 (105.1) 153 (18.8) p < 0.0001 508 (47) 457 (36) 51 (11.4) p < 0.01
Registration
software
9 (1.7) 7 (1.6) 2 (0.2) p < 0.0001 0 (0) 0 (0) 0 (0) 1.000
Total 704 (129.5) 520 (127.2) 184 (22.7) p < 0.0001 602 (56) 541 (42) 61 (13.5) p < 0.01
Fiducial markers Urologist na na na na 20 (0) 22 (7.6) 2 (1.4) 0.36
Nurse na na na na 25 (0) 24 (4.6) 1 (0.9) 0.36
Operating room na na na na 149 (45.9) 140 (52.0) 9 (13.2) 0.48
Fiducial markers na na na na 99(0) 99(0) 0 (0) 1.0
Total na na na na 293 (45.9) 285 (54.9) 8 (13.6) 0.61
Totale 2311 (418.7) 1632 (356.8) 679 (69.6) p < 0.0001 2065 (157) 1878 (135) 187 (39.7) p < 0.0001
a Incremental cost: difference in cost between daily and weekly IGRT frequency.
b Non-parametric test (Wilcoxon and Mann–Whitney tests).
c Internal maintenance and quality control: maintenance and quality control conducted by center staff.
d External maintenance and quality control: subcontracting.
e The total includes only parameters that potentially affected IGRT cost (not the cost of overall treatment).
f Electronic portal imaging.
L. Perrier et al. / Radiotherapy and Oncology 106 (2013) 50–58 553 min at a cost of less than €300 (Table 4). The additional cost of
daily positioning compared to weekly control also appears to be
relatively moderate, at less than €200 for ﬁducial markers, and less
than €700 for CBCT.
The causes of the cost of IGRT also need to be carefully analyzed.
Daily CBCT-based IGRT costs are mostly related to staff (38% of to-
tal costs), while weekly CBCT costs appear relatively more equally
distributed between staff (35% of the IGRT cost), the linear acceler-
ator (33%) and maintenance and quality control (32%) (Table 4).
The causes of ﬁducial-marker-based IGRT costs are more equally
distributed between the three previous cost items (26–29%), but
are also due to the ﬁducial markers themselves (15%). Moreover,
the cost of the accelerator is higher for CBCT than for ﬁducial mark-
ers, due to the higher catalog price of the accelerator with CBCT
(+€438,000). Although staff costs represent the largest proportion
of costs, Figs. 1 and 2 also show that IGRT costs could be reduced
by changing the linear accelerator parameters. The ﬁrst is the an-
nual operating time, which could be increased. Taking the example
of daily CBCT, a 10% increase in the annual operating time of the
accelerator (from 2600 h to 2860 h) would reduce the cost from
€2311 to €2217 (Fig. 1A). The lifetime period parameter could also
be increased to more than 12 years, but with the disadvantage of
not using all the technical innovations of the new generations of
accelerators. The price of the accelerator should also be negotiated
carefully. Furthermore, Figs. 1 and 2 show that decreasing treat-
ment room occupation duration would have also a signiﬁcant im-
pact on IGRT cost (a 10% decrease in duration reduces the mean
cost from €2311 to €2226). However, this objective is not easy to
achieve due to the unavoidable clinical and physical constraints
of the treatments involved. However, continuous advances in com-
puting and imaging may improve both the rapidity and quality ofthe CBCT registration process, while therapists are also more likely
to validate their prostate registrations under the responsibility of
the radiation oncologist and after several months of experience.
Conversely, univariate sensitivity analyses show that a reduction
in unit costs and the duration of staff interventions would have rel-
atively little effect on IGRT costs, except among radiotherapists
(Fig. 2A).
The mean cost of CBCT-based daily control was 43% higher com-
pared with weekly positioning in our study (€2311 vs. €1632). This
is consistent with the ﬁndings of Ploquin et al. (CAN$ 10,579 vs.
CAN$ 7445; i.e.+42%), which also related to prostate cancer treat-
ment (35 fractions) [3]. However, the costs reported in Ploquin
et al.’s study are higher, perhaps because of:
– The exchange rate: CAN$ 1 = €0.72 in 2005 [18].
– The costing methods used: Ploquin et al. used the activity-based
costing methodology, an advanced cost calculation technique
that allocates resource cost to products based on resource con-
sumption including process costs (staff and consumables), clin-
ical infrastructure (major and additional equipment), and
supporting infrastructure (land, building, and administration)
[18–20]. In contrast, our study directly measured staff time
and supply costs (which were limited to process costs and clin-
ical infrastructure due to the considerable time and resources
required to obtain very detailed production data). Supporting
infrastructure costs represent almost 20% of the total cost of
radiotherapy per patient [3]. It is well known that costing meth-
ods impact on the results of economic evaluations [18].
– Ploquin et al.’s study included all radiation therapy processes,
including costs related to assessment of patients’ condition
and disease staging, prescriptions (decisions regarding dose
Fig. 1. Cost-sensitivity of CBCT-based IGRT, with daily (A) or weekly (B) control. These Tornado diagrams illustrate the impact of ±10% variation on the value
of each parameter. The length of each bar represents the extent to which the mean cost is sensitive to this parameter. The graph is laid out so that the most sensitive
parameter (the one with the longest bar) is at the top, and the least sensitive is at the bottom. The vertical line represents the mean cost, when all parameters assume their
base values [9].
56 Cost of IGRTand fractionation scheme), preparation (treatment planning
and the simulation process), and delivery and follow-up (keep-
ing track of health, and so on). Given its labor-intensive nature,
direct measurement was implemented in our study only for
treatment delivery and for resources, which could potentially
affect IGRT costs.
Study limitations
This study has some limitations:
– As micro-costing made by direct measurement using a chro-
nometer requires signiﬁcant resources, our study only used
parameters which could potentially affect IGRT costs. Therefore,the following costs were not taken into account: (i) IGRT pro-
ductivity losses from involved staff related to organizational
constraints or absenteeism (illness or training); (ii) costs of
administrative staff; (iii) medical expenses; and (iv) logistic
and general management costs.
– Our limited time horizon did not enable assessment of all costs
related to treatment strategies, e.g., costs of transportation and
indirect costs.
– Our results indicate that IGRT with CBCT is more expensive than
with ﬁducials, and that IGRT with daily controls is more expen-
sive than with weekly controls. However, the study should be
completed by a cost-effectiveness analysis. The literature
suggests that assessment of the IGRT cost-beneﬁt ratio is
particularly difﬁcult. Only Ploquin et al.’s study included a
Fig. 2. Sensitivity of the cost of electronic portal imaging (EPI) with ﬁducial-marker-based IGRT, with daily (A) or weekly (B) control. These Tornado diagrams illustrate the
impact of ±10% variation on the value of each parameter. The length of each bar represents the extent to which the mean cost is sensitive to this parameter. The graph is laid
out so that the most sensitive parameter (the one with the longest bar) is at the top, and the least sensitive is at the bottom. The vertical line represents the mean cost, when
all the parameters assume their base values [9].
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mal radiotherapy or IMRT [3]. Image guidance was used
solely for translational patient repositioning, and various
imaging modalities and control frequencies were tested. Out-
comes were quantiﬁed using a metric based on equivalent
uniform dose (EUD). The conclusion was that IGRT increased
costs with relatively little improvement in dosimetric quality(incremental EUD < 0.8 Gy), with IMRT beneﬁting more than
3DCRT. We intend to perform a cost-effectiveness analysis
when the clinical results of the randomized trial become
available.
– The assumption of an unchanged stable system for 12 years for
the CBCT system and software also probably results in an
underestimation of the costs.
58 Cost of IGRTConclusion
The costs of the different prostate IGRT strategies (frequency
and modality) are signiﬁcantly different, although incremental
costs are relatively moderate. Our results suggest that the use of
daily IGRT combined with IMRT in cases of high-dose radiation
delivery to the prostate is to be recommended, even if the clinical
beneﬁt of daily control is not yet demonstrated.
Conﬂicts of interests
The authors have no conﬂict of interest to declare.
Role of the funding source
This work was supported by the National Institute of Cancer
(INCa), 52 avenue André Morizet, 92513 Boulogne Billancourt Ce-
dex, for the collection of data.
NCI trial
CSET 1248/NCT0043370.
Acknowledgements
The authors received funding from the National Institute of
Cancer (INCa), and would like to thank Frédéric Bancel, Sophie
Beaupère, Christine Bonhomme, Nathalie Bouvet, Marie-Odile
Carrère, Richard Lefrand, Jacques Pralong, Cédric Prez, Ghislain
Promonet, Raphaël Remonnay, Catherine Romefort, Elodie Terrier
and Benjamin Pitre for their collaboration. The authors would also
like to thank the referees for their insightful comments and
suggestions.
Dr. Sophie MINGUET, Scientiﬁc and Medical Translation, Barce-
lona, Spain, assisted with the ﬁnal editing of the manuscript.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2012.11.
011.
References
[1] Heemsbergen WD, Hoogeman MS, Witte MG, Peeters ST, Incrocci L, Lebesque
JV. Increased risk of biochemical and clinical failure for prostate patients with alarge rectum at radiotherapy planning: results from the Dutch trial of 68 Gy
versus 78 Gy. Int J Radiat Oncol Biol Phys 2007;67:1418–24.
[2] de Crevoisier R, Tucker SL, Dong L, et al. Increased risk of biochemical and local
failure in patients with distended rectum on the planning CT for prostate
cancer radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:965–73.
[3] Ploquin N, Dunscombe P. A cost-outcome analysis of image-guided patient
repositioning in the radiation treatment of cancer of the prostate. Radiother
Oncol 2009;93:25–31.
[4] Gill S, Younie S, Rolfo A, et al. Cost minimisation analysis: kilovoltage imaging
with automated repositioning versus electronic portal imaging in image-
guided radiotherapy. Clin Oncol 2012;24:93–9.
[5] Stroom JC, Heijmen BJ. Geometrical uncertainties, radiotherapy planning
margins, and the ICRU-62 report. Radiother Oncol 2002;64:75–83.
[6] van Herk M, Remeijer P, Rasch C, Lebesque JV. The probability of correct target
dosage: dose-population histograms for deriving treatment margins in
radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:1121–35.
[7] Beckendorf V, Guerif S, Le Prise E, et al. 70 Gy versus 80 Gy in localized prostate
cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol
Phys 2011;80:1056–63.
[8] Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddard GL. Methods
for the economic evaluation of health care programmes. 3rd ed. Oxford
University Press; 2005.
[9] Eschenbach T. Engineering economy: applying theory to practice. 2nd
ed. Oxford University Press; 2010.
[10] Van de Werf E, Verstraete J, Lievens Y. The cost of radiotherapy in a decade of
technology evolution. Radiother Oncol 2012;102:148–53.
[11] Simpson DR, Lawson JD, Nath SK, Rose BS, Mundt AJ, Mell LK. A survey of
image-guided radiation therapy use in the United States. Cancer
2010;116:3953–60.
[12] de Crevoisier R, Pommier P, Bachaud J, et al. Image-guided radiation therapy
(IGRT) in prostate cancer: preliminary results in prostate registration and
acute toxicity of a randomized study. Int J Radiat Oncol Biol Phys 2009;75:99
[abstract].
[13] Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-
dose image guided radiotherapy compared with non-IGRT for the treatment of
clinically localized prostate cancer. Int J Radiat Oncol Biol Phys
2012;84:125–9.
[14] Tuomikoski L, Collan J, Keyrilainen J, Visapaa H, Saarilahti K, Tenhunen M.
Adaptive radiotherapy in muscle invasive urinary bladder cancer–an effective
method to reduce the irradiated bowel volume. Radiother Oncol
2011;99:61–6.
[15] Murthy V, Master Z, Adurkar P, et al. ‘Plan of the day’ adaptive radiotherapy for
bladder cancer using helical tomotherapy. Radiother Oncol 2011;99:55–60.
[16] Gill S, Thomas J, Fox C, et al. Electronic portal imaging vs kilovoltage imaging in
ﬁducial marker image-guided radiotherapy for prostate cancer: an analysis of
set-up uncertainties. Br J Radiol 2012;85:176–82.
[17] Baumann M, Holscher T, Zips D. The future of IGRT – cost beneﬁt analysis. Acta
Oncol 2008;47:1188–92.
[18] Demeere N, Stouthuysen K, Roodhooft F. Time-driven activity-based costing in
an outpatient clinic environment: development, relevance and managerial
impact. Health Policy 2009;92:296–304.
[19] Kaplan RS, Anderson SR. Time-driven activity-based costing. Harv Bus Rev
2004;82:131–8.
[20] Lievens Y, Van den BW, Kesteloot K. Activity-based costing: a practical model
for cost calculation in radiotherapy. Int J Radiat Oncol Biol Phys
2003;57:522–35.
[21] D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after
radical prostatectomy, external beam radiation therapy, or interstitial
radiation therapy for clinically localized prostate cancer. JAMA
1998;280:969–74.
